Overview

A Randomized, Double-blind, Study to Explore the Effect of GED-0301 in Subjects With Active Crohn's Disease

Status:
Completed
Trial end date:
2017-12-14
Target enrollment:
Participant gender:
Summary
This study is design to explore the effect of GED-0301 on clinical and endoscopic outcome and to evaluate its safety in subjects with active Crohn's disease.
Phase:
Phase 1
Details
Lead Sponsor:
Celgene
Celgene Corporation